The DOI matches its Crossref record; 5 of the 6 references it cites were found in a registry or an index; none of the 2 sources its claims cite is checked for support yet.
Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
Open accessAbstract
Persistence of Antibody after mRNA-1273 Vaccination A total of 33 participants who received both doses of the Moderna mRNA-1273 vaccine against SARS-CoV-2 had blood drawn over a period of 6 months ...
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 2 cited sources checked · 0 supported · 0 flagged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 109 days (95% CI, 92 to 136) calculated with the use of a power-law model (at day 119)”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- The authors state this as an assumption: The power-law model assumes that antibody decay rates decrease over time.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 66 days (95% CI, 59 to 72) and 182 days (95% CI, 153 to 254) for live-virus neutralization.”
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- The authors state this as an assumption: The power-law model assumes that antibody decay rates decrease over time.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The estimated half-life of binding antibodies after day 43 for all the participants was 52 days (95% CI, 46 to 58) calculated with the use of an exponential decay model”
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- The authors state this as an assumption: The exponential decay model assumes a constant antibody decay rate over time.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The neutralizing antibody half-life estimates in the two models were 69 days (95% CI, 61 to 76) and 173 days (95% CI, 144 to 225) for pseudovirus neutralization”
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- The authors state this as an assumption: The exponential decay model assumes a constant antibody decay rate over time.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“with 50% inhibitory dilution (ID50) GMTs of 80 (95% CI, 40 to 135), 57 (95% CI, 30 to 106), and 59 (95% CI, 29 to 121), respectively.”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“49,373 (95% CI, 25,171 to 96,849) in those 71 years of age or older.”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As measured by ΔAICc (change in Akaike information criterion, corrected for small sample size), the best fit for binding and neutralization were the power-law and exponential decay models, respectively”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- The authors state this as an assumption: The exponential decay model assumes a constant antibody decay rate over time.
- The authors state this as an assumption: The power-law model assumes that antibody decay rates decrease over time.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“62,424 (95% CI, 36,765 to 105,990) in those 56 to 70 years of age”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The neutralizing antibody half-life estimates in the two models were 69 days (95% CI, 61 to 76) and 173 days (95% CI, 144 to 225) for pseudovirus neutralization”
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- The authors state this as an assumption: The power-law model assumes that antibody decay rates decrease over time.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“these GMTs were lower in participants 56 to 70 years of age (P=0.03) and in those 71 years of age or older (P=0.005) than in those 18 to 55 years of age”
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes
- Probably not a substantial claim. 2
In the paper
“Interim results from a phase 3 trial of the Moderna mRNA-1273 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine indicated 94% efficacy in preventing coronavirus disease 2019 (Covid-19).1”
What the sources say
- Not checked yetcites [1] Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021; 384: 403- 416. 33378609 PMC7787219 source
Strength:hedged· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“These results are consistent with published observations of convalescent patients with Covid-19 through 8 months after symptom onset.5”
What the sources say
- Not checked yetcites [5] Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 2021; 371(6529): eabf4063- eabf4063. 33408181 PMC7919858 source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
The paper relies on this without support.
The durability of protection from the mRNA-1273 vaccine is currently unknown.
“The durability of protection is currently unknown.”
The authors state this as an assumption.
The exponential decay model assumes a constant antibody decay rate over time.
“which assumes a steady decay rate over time”
The authors state this as an assumption.
The power-law model assumes that antibody decay rates decrease over time.
“which assumes that decay rates decrease over time”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Current evidence suggests that circulating antibodies persist for at least 6 months postvaccination (7), although there is some decay from the peak levels achieved after the second dose.”
From mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern (2021) · cites this paper as [7]
In the citing paper
“We previously showed that vaccination with mRNA-1273 elicited antibodies to SARS-CoV-2 WA1 in subjects aged 56 to 70 and 71 and older that are as potent (15) and durable (13) as those elicited in adults aged 18 to 55, with a slight decrease in potency for the oldest subjects in live-virus neutralization (13).”
From Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants (2021) · cites this paper as [13]
In the citing paper
“In the pseudovirus neutralization assay, consistent with our previous study (13), 25% of sera neutralized WA1 after one dose (day 29).”
From Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants (2021) · cites this paper as [13]
In the citing paper
“In clinical trials, two doses of mRNA-1273 also elicited durable antibody responses over a period of 6 months. Although antibody titres declined slightly over the duration of the study, high neutralizing ability was retained across all age groups205.”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [205]
In the citing paper
“Several reports have measured the decay of neutralizing antibody responses raised by mRNA COVID-19 vaccines with a half-life of 69-173 days (Doria-Rose et al., 2021; Levin et al., 2021).”
From mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant (2022) · cites this paper as Doria-Rose et al., 2021
Citations
Cites
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
Self-citationAn mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237
Self-citationImmunological memory to SARS-CoV-2 assessed for up to 8 months after infection.
Dan, J. M., Mateus, J., Kato, Y., Hastie, K. M., Yu, E. D., Faliti, C. E., Grifoni, A., Ramirez, S. I., Haupt, S., Frazier, A., et al. (2021) · Science · doi:10.1126/science.abf4063 · Cited by 2,656
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citationDurability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
Widge, A. T., Rouphael, N. G., Jackson, L. A., Anderson, E. J., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2032195 · Cited by 722
Self-citation
Flagged first, then by citations
1 of the 6 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 101–200 of 646
Gholap, A. D., Gupta, J., Kamandar, P. A., Bhowmik, D. D., Rojekar, S. V., Faiyazuddin, M., Hatvate, N. T., Mohanto, S., Ahmed, M. G., Subramaniyan, V., et al. (2023) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.3c01247 · Cited by 45
COVID-19 Vaccination Scenarios: A Cost-Effectiveness Analysis for Turkey
Hagens, A., İnkaya, A. Ç., Yıldırak, K., Sancar, M., van der Schans, J., Sancar, A. A., Ünal, S., Postma, M. J., & Yeğenoğlu, S. (2021) · Vaccines · doi:10.3390/vaccines9040399 · Cited by 45
COVID ‐19 and plasma cells: Is there long‐lived protection?*
Nguyen, D. C., Lamothe, P. A., Woodruff, M. C., Saini, A. S., Faliti, C. E., Sanz, I., & Lee, F. E.-H. (2022) · Immunological Reviews · doi:10.1111/imr.13115 · Cited by 48
Terpos, E., Trougakos, I. P., Karalis, V. D., Ntanasis‐Stathopoulos, I., Gumeni, S., Apostolakou, F., Sklirou, A. D., Gavriatopoulou, M., Skourti, S., Kastritis, E., et al. (2021) · Cells · doi:10.3390/cells10081942 · Cited by 44
Vaccination of older adults: Influenza, pneumococcal disease, herpes zoster, COVID-19 and beyond
Weinberger, B. (2021) · Immunity & Ageing · doi:10.1186/s12979-021-00249-6 · Cited by 44
SARS‐CoV‐2 vaccination in solid‐organ transplant recipients: What the clinician needs to know
Giannella, M., Pierrotti, L. C., Helanterä, I., & Manuel, O. (2021) · Transplant International · doi:10.1111/tri.14029 · Cited by 43
Coppeta, L., Ferrari, C., Somma, G., Mazza, A., D’Ancona, U., Marcuccilli, F., Grelli, S., Aurilio, M. T., Pietroiusti, A., Magrini, A., et al. (2022) · Vaccines · doi:10.3390/vaccines10020141 · Cited by 42
A systematic review of COVID-19 transport policies and mitigation strategies around the globe
Calderón, F., Cazorla, P., & Avila-Ordóñez, E. (2022) · Transportation Research Interdisciplinary Perspectives · doi:10.1016/j.trip.2022.100653 · Cited by 46
New-onset IgA nephropathy following COVID-19 vaccination
Ma, Y., & Xu, G. (2022) · QJM · doi:10.1093/qjmed/hcac185 · Cited by 42
McKeigue, P., McAllister, D., Hutchinson, S. J., Robertson, C., Stockton, D., & Colhoun, H. M. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00045-5 · Cited by 43
Bonnet, B., Chabrolles, H., Archimbaud, C., Brebion, A., Cosme, J., Dutheil, F., Lambert, C., Junda, M., Mirand, A., Ollier, A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.842912 · Cited by 43
Mades, A., Chellamathu, P., Kojima, N., Lopez, L., MacMullan, M. A., Denny, N., Angel, A. N., Santacruz, M., Casian, J. G., Brobeck, M., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-03931-3 · Cited by 42
Liang, X., Xu, Q., Jia, Z.-J., Wu, M., Liu, Y., Lin, L., Liu, L., & Yang, T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.876037 · Cited by 41
Longitudinal Systemic and Mucosal Immune Responses to SARS-CoV-2 Infection
Wright, P. F., Prevost-Reilly, A., Natarajan, H., Brickley, E. B., Connor, R. I., Wieland‐Alter, W., Miele, A. S., Weiner, J. A., Nerenz, R. D., & Ackerman, M. E. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac065 · Cited by 44
Antibody Persistence 6 Months Post-Vaccination with BNT162b2 among Health Care Workers
Campo, F., Venuti, A., Pimpinelli, F., Abril, E., Blandino, G., Conti, L., VIRGILIO, A. D., Marco, F. D., Noia, V. D., Domenico, E. G. D., et al. (2021) · Vaccines · doi:10.3390/vaccines9101125 · Cited by 40
Ontañón, J., Blas, J., de Cabo, C., Santos, C. P., Taravilla, E. R.-E., García, A., Marı́n, L., Sáez, L., Beato, J. L., Rada, R., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103656 · Cited by 41
COVID-19 Vaccines: Current and Future Perspectives
Soraci, L., Lattanzio, F., Soraci, G., Gambuzza, M. E., Pulvirenti, C., Cozza, A., Corsonello, A., Luciani, F., & Rezza, G. (2022) · Vaccines · doi:10.3390/vaccines10040608 · Cited by 42
Follmann, D. A., O’Brien, M. P., Fintzi, J., Fay, M. P., Montefiori, D. C., Mateja, A., Herman, G. A., Hooper, A. T., Turner, K. C., Chan, K.-C., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39292-w · Cited by 40
Self-citationZhao, Z., Cui, T., Huang, M., Liu, S., Su, X., Li, G., Song, T., Li, W., Zhong, N., Xu, M., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2048969 · Cited by 40
Milo, R., Staun-Ram, E., Karussis, D. M., Karni, A., Hellmann, M. A., Bar‐Haim, E., Miller, A., & The Israeli Neuroimmunology Study Group on COVID-19 Vaccination in Multiple Sclerosis (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.868915 · Cited by 40
Lv, J., Wu, H., Xu, J., & Liu, J. (2022) · Infectious Diseases of Poverty · doi:10.1186/s40249-022-00977-x · Cited by 40
Komori, M., Nogimori, T., Morey, A. L., Sekida, T., Ishimoto, K., Hassett, M. R., Masuta, Y., Ode, H., Tamura, T., Suzuki, R., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38457-x · Cited by 39
Collatuzzo, G., Visci, G., Violante, F. S., Porru, S., Spiteri, G., Monaco, M. G. L., Fillon, F. L., Negro, C., Janke, C., Castelletti, N., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.986085 · Cited by 40
Padoan, A., Cosma, C., Bonfante, F., Rocca, F. D., Barbaro, F., Santarossa, C., Dall’Olmo, L., Pagliari, M., Bortolami, A., Cattelan, A. M., et al. (2021) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2021-1247 · Cited by 40
Haveri, A., Solastie, A., Ekström, N., Österlund, P., Nohynek, H., Nieminen, T. A., PALMU, A. A. I., & Melin, M. M. (2022) · European Journal of Immunology · doi:10.1002/eji.202149785 · Cited by 41
Yu, X., Wei, D., Xu, W., Liu, C., Guo, W., Li, X., Tan, W., Liu, L., Zhang, X., Qu, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29477-0 · Cited by 38
SARS-CoV-2: An Updated Review Highlighting Its Evolution and Treatments
Zhang, X., Yuan, H., Yang, Z., Hu, X., Mahmmod, Y. S., Zhu, X., Zhao, C., Zhai, J., Zhang, X., Luo, S., et al. (2022) · Vaccines · doi:10.3390/vaccines10122145 · Cited by 38
Hossain, M. E., Islam, M. S., Rana, M. J., Amin, M. R., Rokonuzzaman, M., Chakrobortty, S., & Saha, S. M. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.2022920 · Cited by 38
Gopinath, S., Ishak, A., Dhawan, N., Poudel, S., Shrestha, P. S., Singh, P., Xie, E., Tahir, P., Marzaban, S., Michel, J., et al. (2022) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed7050081 · Cited by 39
Praet, J. T. V., Vandecasteele, S. J., Roo, A. D., Vynck, M., Vriese, A. S. D., & Reynders, M. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab458 · Cited by 37
Zhao, W., Chen, W., Li, J., Chen, M., Li, Q., Lv, M., Zhou, S., Bai, S., Wang, Y., Zhang, L., et al. (2022) · mBio · doi:10.1128/mbio.00181-22 · Cited by 37
Guo, W., Duan, K., Zhang, Y., Yuan, Z., Zhang, Y., Wang, Z., Zhao, D., Zhang, H., Xie, Z., Li, X., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101010 · Cited by 36
Long-Term Analysis of Antibodies Elicited by Sputnik V in Tucuman, Argentina
Chahla, R. E., Tomas‐Grau, R. H., Cazorla, S. I., Ploper, D., Pingitore, E. V., López, M. A., Aznar, P., Alcorta, M. E., Vélez, E. M. D. M., Stagnetto, A., et al. (2021) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2021.100123 · Cited by 37
Singh, A. K., Phatak, S., Singh, R., Bhattacharjee, K., Singh, N. K., Gupta, A., & Sharma, A. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102424 · Cited by 36
Almendro-Vázquez, P., Chivite‐Lacaba, M., Utrero‐Rico, A., González‐Cuadrado, C., Laguna‐Goya, R., Moreno-Batanero, M., Sánchez-Paz, L., Luczkowiak, J., Labiod, N., Folgueira, M. D., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.981350 · Cited by 37
Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseases
Rouf, N. Z., Biswas, S., Tarannum, N., Oishee, L. M., & Muna, M. M. (2022) · RNA Biology · doi:10.1080/15476286.2022.2055923 · Cited by 39
Serological response to COVID-19 vaccination in patients with cancer older than 80 years
Iacono, D., Cerbone, L., Palombi, L., Cavalieri, E., Sperduti, I., Cocchiara, R. A., Mariani, B., Parisi, G., & Garufi, C. (2021) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2021.06.002 · Cited by 35
Duengelhoef, P. M., Hartl, J., Rüther, D. F., Steinmann, S., Brehm, T. T., Weltzsch, J. P., Glaser, F., Schaub, G., Sterneck, M. R., Sebode, M., et al. (2022) · United European Gastroenterology Journal · doi:10.1002/ueg2.12218 · Cited by 35
Anderson, E. M., Li, S. H., Awofolaju, M., Eilola, T., Goodwin, E. C., Bolton, M. J., Gouma, S., Manzoni, T. B., Hicks, P. D., Goel, R. R., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111496 · Cited by 37
Self-citationViana, J. F., Bergman, M., Gonçalves, L. A., Duarte, N., Coutinho, T. P., Borges, P., Diwo, C., Castro, R., Matoso, P., Malheiro, V., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27761-z · Cited by 35
Tré‐Hardy, M., Cupaiolo, R., Wilmet, A., Beukinga, I., & Blairon, L. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.06.017 · Cited by 33
Parry, H., McIlroy, G., Bruton, R. K., Damery, S. L., Tyson, G. B., Logan, N. A., Davis, C., Willett, B. J., Zuo, J., Ali, M., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01219-7 · Cited by 33
Sobieszczyk, M. E., Maaske, J., Falsey, A. R., Sproule, S., Robb, M. L., Frenck, R. W., Tieu, H., Mayer, K. H., Corey, L., Neuzil, K. M., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci160565 · Cited by 33
Self-citationWang, S., Wang, C. Y., Kuo, H.-K., Peng, W., Huang, J.-H., Kuo, B.-S., Feng, L., Liu, Y.-J., Liu, Z., Wu, H.-T., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2140608 · Cited by 33
An Update on Anti-COVID-19 Vaccines and the Challenges to Protect Against New SARS-CoV-2 Variants
Mambelli, F., de Araujo, A. C. V. S. C., Farias, J. P., de Andrade, K. Q., Ferreira, L. C. D. S., Minoprio, P. M. C., Leite, L. C. C., & Oliveira, S. C. (2025) · Pathogens · doi:10.3390/pathogens14010023 · Cited by 32
Rodrigues, K. A., Rodriguez‐Aponte, S. A., Dalvie, N. C., Lee, J. H., Abraham, W. D., Carnathan, D. G., Jimenez, L. E., Ngo, J. T., Chang, J. Y. H., Zhang, Z., et al. (2021) · Science Advances · doi:10.1126/sciadv.abj6538 · Cited by 36
Dyer, A. H., Noonan, C., McElheron, M., Batten, I., Reddy, C., Connolly, E., Pierpoint, R., Murray, C., Leonard, A., Higgins, C., et al. (2022) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2021.12.001 · Cited by 32
Ngandu, N. K., Mmotsa, T. M., Dassaye, R., Thabetha, A., Odendaal, W., Langdown, N., & Ndwandwe, D. E. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07128-5 · Cited by 32
Li, M., Yang, J., Wang, L., Wu, Q., Wu, Z., Zheng, W., Wang, L., Lu, W., Deng, X., Peng, C., et al. (2021) · medRxiv · doi:10.1101/2021.08.03.21261544 · Cited by 32
Piñana, J. L., Martino, R., Vázquez, L., López‐Corral, L., Pérez, A., Chorão, P., Avendaño, A., Pascual, M., Sánchez‐Salinas, A., Sanz‐Linares, G., et al. (2023) · Bone Marrow Transplantation · doi:10.1038/s41409-023-01946-0 · Cited by 31
The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccinesPreprint
Liu, Y., Arase, N., Kishikawa, J.-I., Hirose, M., Li, S., Tada, A., Matsuoka, S., Arakawa, A., Akamatsu, K., Ono, C., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.22.457114 · Cited by 31
Ferrari, D., Clementi, N., Criscuolo, E., Ambrosi, A., Corea, F., Resta, C. D., Tomaiuolo, R., Mancini, N., Locatelli, M., Plebani, M., et al. (2021) · Vaccines · doi:10.3390/vaccines9111357 · Cited by 31
Lázaro-Frías, A., Pérez, P., Zamora, C., Sánchez‐Cordón, P. J., Guzmán, M. G., Luczkowiak, J., Delgado, R. B., Casasnovas, J. M., Estéban, M., & García‐Arriaza, J. (2022) · npj Vaccines · doi:10.1038/s41541-022-00440-w · Cited by 30
Jin, L., Tang, R., Wu, S., Guo, X., Huang, H., Hou, L., Chen, X., Zhu, T., Gou, J.-B., Zhong, J., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2155251 · Cited by 30
Application of Artificial Intelligence in COVID-19 Diagnosis and Therapeutics
Asada, K., Komatsu, M., Shimoyama, R., Takasawa, K., Shinkai, N., Sakai, A., Bolatkan, A., Yamada, M., Takahashi, S., Machino, H., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11090886 · Cited by 30
Nucleic acid delivery and nanoparticle design for COVID vaccines
Andresen, J. L., & Fenton, O. S. (2021) · MRS Bulletin · doi:10.1557/s43577-021-00169-2 · Cited by 32
Dynamics of antibody response to BNT162b2 mRNA COVID-19 vaccine after 6 months
Ponticelli, D., Antonazzo, I. C., Caci, G., Vitale, A., Ragione, G. D., Romano, M. L., Borrelli, M., Schiavone, B., Polosa, R., & Ferrara, P. (2021) · Journal of Travel Medicine · doi:10.1093/jtm/taab173 · Cited by 28
Stevens, K., Frangou, E. A., Shin, J. I., Anders, H., Bruchfeld, A. N., Schönermarck, U., Hauser, T., Westman, K. W. A., Juarez, G. M. F., Floege, J., et al. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac052 · Cited by 28
Terpos, E., Karalis, V. D., Ntanasis‐Stathopoulos, I., Gavriatopoulou, M., Gumeni, S., Malandrakis, P., Papanagnou, E., Kastritis, E., Trougakos, I. P., & Dimopoulos, M. A. (2021) · Life · doi:10.3390/life11101077 · Cited by 27
The mRNA vaccine, a swift warhead against a moving infectious disease target
Mir, S., & Mir, M. A. (2024) · Expert Review of Vaccines · doi:10.1080/14760584.2024.2320327 · Cited by 28
Seroprevalence and levels of IgG antibodies after COVID-19 infection or vaccination
Soeorg, H., Jõgi, P., Naaber, P., Ottas, A., Toompere, K., & Lutsar, I. (2021) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2021.1974540 · Cited by 28
The temporal course of T- and B-cell responses to vaccination with BNT162b2 and mRNA-1273
Markewitz, R. D. H., Pauli, D., Dargvainiene, J., Steinhagen, K., Engel, S., Herbst, V., Zapf, D., Krüger, C., Sharifzadeh, S. R., Schomburg, B., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.09.006 · Cited by 27
Beta RBD boost broadens antibody-mediated protection against SARS-CoV-2 variants in animal models
Sheward, D. J., Mandolesi, M., Urgard, E., Kim, C., Hanke, L., Vidakovics, L. P., Pankow, A. P., Smith, N. L., Dopico, X. C., McInerney, G. M., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100450 · Cited by 28
Triple jeopardy in ageing: COVID-19, co-morbidities and inflamm-ageing
Rea, I. M., & Alexander, H. D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101494 · Cited by 27
Bai, J., Chiba, A., Murayama, G., Kuga, T., Tamura, N., & Miyake, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.786586 · Cited by 27
Hsieh, S., Chang, S., Cheng, H., Shih, S., & Lien, C.-E. (2022) · Infectious Diseases and Therapy · doi:10.1007/s40121-022-00652-6 · Cited by 27
Pušnik, J., König, J., Mai, K., Richter, E., Zorn, J., Proksch, H., Schulte, B., Alter, G., & Streeck, H. (2022) · Journal of Virology · doi:10.1128/jvi.00760-22 · Cited by 29
Gil-Manso, S., Carbonell, D., López-Fernández, L. A., Miguens, I., Alonso, R., Buño, I., Muñóz, P., Ochando, J., Pion, M., & Correa‐Rocha, R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.726960 · Cited by 26
Milligan, E. C., Olstad, K. J., Williams, C. A., Mallory, M. L., Cano, P., Cross, K., Munt, J. E., Garrido, C., Lindesmith, L. C., Watanabe, J., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.add6383 · Cited by 27
Self-citationWhy promoting a COVID-19 vaccine booster dose?
Loubet, P., Laureillard, D., Martin, A., Larcher, R., & Sotto, A. (2021) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2021.100967 · Cited by 27
Progress Update on STING Agonists as Vaccine Adjuvants
Shen, Y., Huang, W., Nie, J., & Zhang, L. (2025) · Vaccines · doi:10.3390/vaccines13040371 · Cited by 26
Factors Affecting the Antibody Immunogenicity of Vaccines against SARS-CoV-2: A Focused Review
Cheng, Z. J., Xue, M., Zheng, P., Lyu, J., Zhan, Z., Hu, H., Zhang, Y., Zhang, X. D., & Sun, B. (2021) · Vaccines · doi:10.3390/vaccines9080869 · Cited by 26
Dulovic, A., Strengert, M., Ramos, G. M., Becker, M., Griesbaum, J., Junker, D., Lürken, K., Beigel, A., Wrenger, E., Lonnemann, G., et al. (2022) · Emerging infectious diseases · doi:10.3201/eid2804.211907 · Cited by 25
Giuliano, A. R., Lancet, J. E., Pilon‐Thomas, S., Dong, N. C., Jain, A. G., Tan, E. S., Ball, S., Tworoger, S. S., Siegel, E. M., Whiting, J., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.0001 · Cited by 25
Jamshidi, E., Asgary, A., Shafiekhani, P., Khajeamiri, Y., Mohamed, K., Esmaily, H., Rahi, S. J., & Mansouri, N. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2037384 · Cited by 25
Chen, X., Wang, W., Chen, X., Wu, Q., Sun, R., Ge, S., Zheng, N., Lu, W., Yang, J., Rodewald, L. E., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02249-9 · Cited by 25
Multiplexed LNP-mRNA vaccination against pathogenic coronavirus species
Peng, L., Fang, Z., Renauer, P. A., McNamara, A., Park, J. J.-Y., Lin, Q., Zhou, X., Dong, M. B., Zhu, B., Zhao, H., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111160 · Cited by 26
Frey, S. M., Chiang, T. P., Connolly, C. M., Teles, M. S., Alejo, J. L., Boyarsky, B. J., Christopher‐Stine, L., Werbel, W. A., Massie, A. B., Segev, D. L., et al. (2022) · The Lancet Rheumatology · doi:10.1016/s2665-9913(21)00417-3 · Cited by 24
Jutel, M., Torres, M. J., Palomares, Ó., Akdiş, C. A., Eiwegger, T., Untersmayr, E., Barber, D., Zemelka‐Wiącek, M., Kosowska, A., Palmer, E. N., et al. (2022) · Allergy · doi:10.1111/all.15252 · Cited by 25
Κοντοπούλου, Κ., Nakas, C. T., & Papazisis, G. (2022) · Vaccines · doi:10.3390/vaccines10060876 · Cited by 24
Establishing long-lasting vaccine immunity: insights from mRNA and adjuvanted protein platforms
Pineda-Peña, A.-C., Hasegawa, K., Pavot, V., Berry, C., Combadière, B., Cortés-Garcia, G., McDermott, A. B., & Sridhar, S. (2025) · npj Vaccines · doi:10.1038/s41541-025-01302-x · Cited by 23
Self-citationZhang, R., Khong, K.-W., Leung, K., Liu, D., Fan, Y., Lu, L., Chan, P.-C., Chen, L., To, K. K., Chen, H., et al. (2021) · Vaccines · doi:10.3390/vaccines9121442 · Cited by 24
Monitoring of SARS-CoV-2 Specific Antibodies after Vaccination
Guiomar, R., Santos, A. J., Melo, A. M., Costa, I., Matos, R., Rodrigues, A. P., Kislaya, I., Silva, A. S., Roque, C., Nunes, C., et al. (2022) · Vaccines · doi:10.3390/vaccines10020154 · Cited by 24
Li, L., Müftüoğlu, M., Liang, S., Basyal, M., Lv, J., Akdogan, M. E., Chen, K., Andreeff, M., Flowers, C. R., & Parmar, S. (2022) · JCI Insight · doi:10.1172/jci.insight.156559 · Cited by 24
Hua, Q., Zhang, H., Yao, P., Xu, N., Sun, Y., Lu, H.-J., Xu, F., Liao, Y., Yang, J., Mao, H., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.939311 · Cited by 25
Current Progress, Challenges and Prospects in the Development of COVID-19 Vaccines
Zhu, C., Pang, S., Liu, J., & Duan, Q. (2024) · Drugs · doi:10.1007/s40265-024-02013-8 · Cited by 24
Ledda, C., Costantino, C., Motta, G., Cunsolo, R., Stracquadanio, P., Liberti, G., Maltezou, H. C., & Rapisarda, V. (2022) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed7010009 · Cited by 22
Bormann, M., Brochhagen, L., Alt, M., Otte, M., Thümmler, L., van de Sand, L., Kraiselburd, I., Thomas, A. R., Gosch, J., Braß, P., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1150667 · Cited by 22
Fiolet, T., Kherabi, Y., MacDonald, C. J., Ghosn, J., & Peiffer‐Smadja, N. (2021) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/z4x7t · Cited by 22
Tadmor, T., Benjamini, O., Braester, A., Rahav, G., & Rokach, L. (2021) · Leukemia · doi:10.1038/s41375-021-01380-5 · Cited by 21
COVID-19 health passes: current status and prospects for a global approach
Chen, L. H., Petersen, E., Blumberg, L. H., Piyaphanee, W., & Steffen, R. J. (2021) · Journal of Travel Medicine · doi:10.1093/jtm/taab118 · Cited by 21
Persistence of Anti-S Titre among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19
Coppeta, L., Somma, G., Ferrari, C., Mazza, A., Rizza, S., Aurilio, M. T., Perrone, S., Magrini, A., & Pietroiusti, A. (2021) · Vaccines · doi:10.3390/vaccines9090947 · Cited by 21
Sidler, D., Born, A., Schietzel, S., Horn, M. P., Aeberli, D., Amsler, J., Möller, B., Njue, L. M., Medri, C., Angelillo‐Scherrer, A., et al. (2022) · RMD Open · doi:10.1136/rmdopen-2021-002166 · Cited by 21
Inchingolo, A. D., Malcangi, G., Ceci, S., Patano, A., Corriero, A., Vimercati, L., Azzollini, D., Marinelli, G., Coloccia, G., Piras, F., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158485 · Cited by 22
Xue, P., Merikanto, I., Chung, F. F., Morin, C. M., Espie, C. A., Bjorvatn, B., Cedernaes, J., Landtblom, A., Penzel, T., Gennaro, L. D., et al. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02334-4 · Cited by 21
Herishanu, Y., Avivi, I. M., Levi, S., Shefer, G., Bronstein, Y., Morales, M., Ziv, T., Scarfò, L., Perry, C., & Ghia, P. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005998 · Cited by 21
Impact of prior vaccination on clinical outcomes of patients with COVID-19
Seo, W. J., Kang, J., Kang, H. K., Park, S. H., Koo, H., Park, H. K., Lee, S.-S., Song, J. E., Kwak, Y. G., & Kang, J. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2069516 · Cited by 22
Cohen, J. A., Stuart, R. M., Rosenfeld, K., Lyons, H. M., White, M. T., Kerr, C. C., Klein, D. J., & Famulare, M. (2021) · medRxiv · doi:10.1101/2021.05.31.21258018 · Cited by 21
Terpos, E., Karalis, V., Ntanasis‐Stathopoulos, I., Apostolakou, F., Gumeni, S., Gavriatopoulou, M., Papadopoulos, D., Malandrakis, P., Papanagnou, E.-D., Korompoki, E., et al. (2021) · HemaSphere · doi:10.1097/hs9.0000000000000677 · Cited by 20
Hewins, B., Rahman, M., Bermejo-Martín, J. F., Kelvin, A. A., Richardson, C. D., Rubino, S., Kumar, A., Ndishimye, P., Ostadgavahi, A. T., Mahmud-Al-Rafat, A., et al. (2022) · Frontiers in Virology · doi:10.3389/fviro.2022.849936 · Cited by 21
Metadata
- Authors
- Doria-Rose, N., Suthar, M. S., Makowski, M., O’Connell, S., McDermott, A. B., Flach, B., Ledgerwood, J. E., Mascola, J. R., Graham, B. S., Lin, B. C., O’Dell, S., Schmidt, S. D., Widge, A. T., Edara, V.-V., Anderson, E. J., Lai, L., Floyd, K., Rouphael, N. G., Zarnitsyna, V., Roberts, P. C., Makhene, M., Buchanan, W., Luke, C. J., Beigel, J. H., Jackson, L. A., Neuzil, K. M., Bennett, H., Leav, B., Albert, J., & Kunwar, P.
- Affiliations
- National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD
- Emory University (US)
- Emmes (United States) (US)
- National Institutes of Health (US)
- NIAID, Bethesda, MD
- Kaiser Permanente Washington Health Research Institute (US)
- University of Maryland, Baltimore (US)
- Moderna Therapeutics (United States) (US)
- Corresponding author
- Suthar, Mehul S.
- ORCID
- Doria-Rose, Nicole
- Suthar, Mehul S.
- Makowski, Mat
- O’Connell, Sarah
- McDermott, Adrian B.
- Ledgerwood, Julie E.
- Mascola, John R.
- Graham, Barney S.
- Lin, Bob C.
- Schmidt, Stephen D.
- Widge, Alicia T.
- Edara, Venkata-Viswanadh
- Anderson, Evan J.
- Lai, Lilin
- Floyd, Katharine
- Rouphael, Nadine G.
- Zarnitsyna, Veronika
- Roberts, Paul C.
- Beigel, John H.
- Jackson, Lisa A.
- Neuzil, Kathleen M.
- Bennett, Hamilton
- Leav, Brett
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-06-10
- Volume
- 384
- Issue
- 23
- Pages
- 2259-2261
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8524784
- OpenAlex
- W3142193311
- Cited by
- 673
- References
- 6
- Citations by year
- 2026: 17 · 2025: 25 · 2024: 40 · 2023: 104 · 2022: 287 · 2021: 199
- FWCI
- 49.96
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Covid-Catalyst-I3 Funds from the Woodruff Health Sciences Center and Emory School of Medicine
- North Carolina Policy Collaboratory at the University of North Carolina at Chapel Hill
- North Carolina Coronavirus Relief Fund
- Coalition for Epidemic Preparedness Innovations
- Georgia Research Alliance
- National Institute of Allergy and Infectious Diseases (AI149644, HHSN272201500002C, P51 OD011132, UM1AI148373, UM1AI148576, UM1AI148684, UM1Al148684-01S1)
- National Center for Advancing Translational Sciences (UL1 TR002243)
- Dolly Parton COVID-19 Research Fund
- Emory Executive Vice President for Health Affairs Synergy Fund award
- Center for Childhood Infections and Vaccines
- Children’s Healthcare of Atlanta
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccination, antibody persistence, humoral immune response, Moderna vaccine, booster vaccination, SARS-CoV-2 antibodies
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adult, Aged, Antibodies, Viral, Half-Life, Humans, Middle Aged, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
